86 results about "Management of prostate cancer" patented technology

The present inventors investigated the antitumor effects of anti-IL-6 receptor antibodies against prostate cancer. The result showed that the anti-IL-6 receptor antibodies had both in vivo and in vitro antitumor effects against prostate cancer. It was also revealed that the hPM1 antitumor effect is via IL-6 receptor.

An improved method and products for the primary hormonal treatment of early stage, low and intermediate risk prostate cancers by prostatic implants of androgen suppressive drugs formulated as fused with a lipoid carrier or encapsulated in microcapsules or in Silastic capsules is provided. Such prostatic implants renders a constant slow-release of their contents to the prostate for extended periods by biodegradation and diffusion. It facilitates higher prostatic and lower systemic concentrations of androgen suppressive hormones. Because of their high prostatic and lower systemic concentrations, tumor control is much improved and the their systemic toxicity is minimized. Tumor control after such primary hormonal implant treatment is followed by clinical examinations and the biochemical tumor control is followed by periodic estimations of serum levels of PSA and acid phosphatase. More complex and expensive surgery or radiation therapy for this group of good prognostic early stage prostate cancer is reserved for those patients failing to this primary hormonal treatment. It will preserve potency more than by surgery or radiation therapy. Furthermore, it would reduce the cost of treatment for early stage prostate cancer significantly. Androgen suppressive hormonal implants to the prostate before, during or after lower dose conventional radiation therapy would also facilitate equal or better cure rates of localized prostate cancer as compared to the more complex and toxic higher dose radiation therapy.

The invention relates to a method for treating ERG-positive prostate cancer patients with an agent counteracting one or more ERG-associated genes and/or manipulating of one or more ERG-related pathways, optionally in combination with an androgen deprivation therapy. Furthermore, the invention concerns methods for screening prostate cancer patients which may benefit from said treatment, assessing the efficacy of a therapy for treating prostate cancer in a patient, assessing progression of prostate cancer in a patient, selecting an agent to be tested for usefulness in the treatment of prostate cancer, and for assessing prostate carcinogenic potential of an agent.

The present invention related to methods for treating neurological-urological conditions associated with prostate cancer or methods of treatment of prostate cancer, which is accomplished by administration of botulinum toxin to the patient.

According to the present invention, an apoptosis-inducing agent for prostate cancer comprising REIC/Dkk-3 DNA or an REIC/Dkk-3 protein, and a therapeutic agent for prostate cancer and an agent for inhibiting prostate cancer metastasis that comprise such apoptosis-inducing agent are provided.

An apoptosis-inducing agent for prostate cancer, comprising, as an active ingredient, an REIC/Dkk-3 protein (a) or (b) or REIC/Dkk-3 DNA (c) or (d):

• • (a) a protein consisting of the amino acid sequence represented by SEQ ID NO: 2;
  • (b) a protein consisting of an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 2 by substitution or deletion of 1 or more amino acids;
  • (c) DNA consisting of the nucleotide sequence represented by SEQ ID NO: 1; or
  • (d) DNA that hybridizes under stringent conditions to DNA consisting of a nucleotide sequence complementary to the nucleotide sequence represented by SEQ ID NO: 1 and encodes a protein having apoptosis activity; and
  • a therapeutic agent for prostate cancer comprising such apoptosis-inducing agent are provided

The invention discloses a purification method for two active monomer compounds in saxifrage and application of product of the same. The method is as below: extracting saxifrage with ethanol; extracting the extract successively with petroleum ether and ethyl acetate; and separating the ethyl acetate extract by silica gel column chromatography, medium pressure column chromatography and gel column chromatography, so as to separate out the two monomer compounds (quercetin 3-O-beta-L-rhamnoside, quercetin 5-O-beta-D glucoside) from saxifrage. Biological activity determination results indicate that the saxifrage extract and the two monomer compounds have good inhibition effect on growth and proliferation of prostate cancer cells, can be used in preparation of medicine for treating prostate cancer, and have good application prospects in drugs for treating prostate cancer.

The invention discloses a targeting gene-viro-therapy medicine specific for prostate cancer. An adenovirus is used, a natural promoter of an early gene EIA of the adenovirus is replaced by a promoter DD3 specific for the prostate cancer, and an oncolytic adenovirus is formed and carries anti-oncogene PTEN specific for the prostate cancer. If the anti-cancer effect of the anti-oncogene PTEN is not strong enough and is insufficient to completely kill the cancer, genes such as TRAIL, IL-24, MNSOD, CD, Smac, GM-CSF, IFN, IL-12, p53, RNAi, microRNA, Caspase 3 and Bax can added to the same carrier to be commonly used with the anti-oncogene PTEN, or two genes are linked to used through various schemes. The gene-viro-therapy medicine specific for the prostate cancer has high targeting treatment effect on the prostate cancer and basically has no influence on normal cells.

The present invention relates complexes comprising a PSMA targeting compound linked to a radionuclide, such as ²¹²Pb or ²²⁷Th. These compounds, and pharmaceutical compositions comprising them, can be used for medical applications. These applications include the treatment of prostate cancer, and the complexes allow for dual targeting of cancers.

Inactive precursor forms of PSA (pPSA) have been identified to exist in serum and tissues of patients with prostate cancer. Antibodies specific for pPSA are provided. Methods for detecting inactive precursors of PSA in human physiological fluid and tissues are also provided, as well as diagnostic kits and methods useful in the diagnosis and management of prostate cancer.

The invention provides ZNF695 as a marker and a treatment target of prostate cancer bone metastasis. It is determined that the ZNF695 is highly expressed in a prostate cancer tissue and is particularly specific in the prostate cancer tissue accompanied by bone metastasis, and in-vivo prostate cancer bone metastasis can be remarkably inhibited by down-regulation of the ZNF695. Therefore, the ZNF695can be used as an early diagnosis marker of prostate cancer and bone metastasis thereof and a treatment target of prostate cancer.

The invention discloses a plasmid expressed by prostate-specific antigen (PSA) promoter mediated firefly luciferase gene. The plasmid is formed by connecting a PSA promoter pPSA-ZsGreen dominant skeleton with a firefly luciferase gene fragment. The plasmid is applied to the transfection of prostate cancer cells to lay a foundation for constructing a prostate PSA fluorescence reporter gene animal model. The part of the tumor in the prostate cancer animal model is positioned by use of fluorescence, and then a reliable animal model can be provided for the treatment of the prostate cancer and the development of new drugs.